Skip to main navigation

>> Site Menu

Our Company
Our Science
Focus Areas
Our Pipeline
Our Culture
INVESTORS & MEDIA

Kodiak Sciences

>> Site Menu

Our Company
Our Science
Focus Areas
Our Pipeline
Our Culture
INVESTORS & MEDIA

News Releases

> News - Sub Nav

Press Releases

News Releases

Year

September 8, 2023

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Additional Formats

PDF Version

September 7, 2023

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Additional Formats

PDF Version

August 14, 2023

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

July 24, 2023

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

Additional Formats

PDF Version

May 30, 2023

Kodiak Sciences to Present at Upcoming Investor Conferences

Additional Formats

PDF Version

May 15, 2023

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

April 21, 2023

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Additional Formats

PDF Version

April 3, 2023

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

Additional Formats

PDF Version

March 28, 2023

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

February 9, 2023

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 11

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter

Copyright © 2023 Kodiak Sciences Inc. MOBILE APP PRIVACY POLICY